69189-19-1

Usage

Uses

Used in Organic Synthesis:
4-broMo-1,2-bis(broMoMethyl)benzene is used as a building block in the production of various materials and pharmaceuticals. Its unique structure allows for the creation of a wide range of compounds with diverse applications.
Used as a Reagent in Chemical Reactions:
In the field of chemistry, 4-broMo-1,2-bis(broMoMethyl)benzene serves as a reagent to introduce bromomethyl groups into other molecules. This property is valuable for the synthesis of new compounds and the modification of existing ones.
Used in Pharmaceutical Industry:
4-broMo-1,2-bis(broMoMethyl)benzene has been studied for its potential anti-cancer and anti-inflammatory properties, making it of interest to the pharmaceutical industry. Its ability to target specific biological pathways and modulate cellular processes could lead to the development of new therapeutic agents.
Used in Research and Development:
Due to its unique chemical properties and potential applications, 4-broMo-1,2-bis(broMoMethyl)benzene is also used in research and development to explore new methods of synthesis, understand its interactions with other molecules, and evaluate its efficacy in various applications.
It is important to handle 4-broMo-1,2-bis(broMoMethyl)benzene with care due to its potential toxicity and irritancy. Proper safety measures should be taken during its production, use, and disposal to minimize risks to human health and the environment.

Upstream product

• 171011-37-3 4-bromo-2-(hydroxymethyl)benzyl alcohol 
• 86-90-8 4-bromophthalic anhydride 

Downstream Products

• 64169-34-2 5-bromophthalide 
• 1618090-65-5 tert-butyl 3-((2R)-[[2-[2-[(Z)-N,N'-bis(tert-butoxycarbonyl)carbamimidoyl]isoindolin-5-yl]acetyl]amino]-2-(2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0^2,6]dec-4-yl)ethyl)-2-methoxybenzoate 
• 1618083-61-6 tert-butyl 3-((2R)-2-((isoindolin-5-yl)acetamido)-2-(2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0^2,6]dec-4-yl)ethyl)-2-methoxybenzoate 
• 1618083-60-5 tert-butyl 3-((2R)-2-((2-benzyloxycarbonylisoindolin-5-yl)acetamido)-2-(2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0^2,6]dec-4-yl)ethyl)-2-methoxybenzoate 
• 1618083-59-2 2-(2-benzyloxycarbonylisoindolin-5-yl)acetic acid 
• 1618083-58-1 benzyl 5-(2-oxoethyl)isoindoline-2-carboxylate 
• 1618083-57-0 benzyl 5-(2,3-dihydroxypropyl)isoindoline-2-carboxylate 
• 1618083-56-9 benzyl 5-allylisoindoline-2-carboxylate 
• 178445-27-7 benzyl 5-bromoisoindoline-2-carboxylate 
• 127168-84-7 5-bromoisoindoline 
• 1609574-36-8 3-[3,4-bis(tert-butoxycarboinylaminoethyl)phenyl]propan-1-ol 
• 1609574-33-5 methyl 3-[3,4-bis(tert-butoxycarboinylaminoethyl)phenyl]propanoate 
• 1609574-30-2 (E)-methyl 3-[3,4-bis(tert-butoxycarbonylaminoethyl)phenyl]acrylate 
• 1609568-26-4 4-bromo-1,2-bis(1,3-dimethylimidazolin-2-ylideneaminomethyl)benzene 

Relevant academic research and scientific papers

Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens

Pentamidine, an FDA-approved antiparasitic drug, was recently identified as an outer membrane disrupting synergist that potentiates erythromycin, rifampicin, and novobiocin against Gram-negative bacteria. The same study also described a preliminary structure-activity relationship using commercially available pentamidine analogues. We here report the design, synthesis, and evaluation of a broader panel of bis-amidines inspired by pentamidine. The present study both validates the previously observed synergistic activity reported for pentamidine, while further assessing the capacity for structurally similar bis-amidines to also potentiate Gram-positive specific antibiotics against Gram-negative pathogens. Among the bis-amidines prepared, a number of them were found to exhibit synergistic activity greater than pentamidine. These synergists were shown to effectively potentiate the activity of Gram-positive specific antibiotics against multiple Gram-negative pathogens such as Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli, including polymyxin- and carbapenem-resistant strains.

IDO/TDO Inhibitor

A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, R1 and R2 represent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and R1 and R2 are the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, R4 represents, for example, —C(═NH)—HN2, and R6 represents, for example, a substituted or unsubstituted aryl group].

Synthesis of 8-bromo-5,12-tetracenequinone and 2-bromotetracene derivatives

A series of bromotetracenequinones 1 and bromotetracenes 2 were prepared from 4-bromophthalic anhydride. The parent tetracenequinone 1a and tetracene 2a were sparingly soluble in organic solvents. In contrast, dipropyl-substituted tetracenequinone 1b and

Immobilized 1,2-bis(guanidinoalkyl)benzenes: Potentially useful for the purification of arsenic-polluted water

Guanidines can act as ligands for various organic and inorganic ions. We have previously synthesized polymer-supported aromatic bisguanidine derivatives and evaluated their potential for removing arsenic from polluted water. In this work, we designed and

AMINO ACID COMPOUNDS

[Problem] To provide novel compounds that are S1P1 receptor agonists and exhibit an immunosuppressive activities by inducing lymphocyte sequestration in secondary lymphoid tissues. In addition, to provide a pharmaceutical agent which comprises the compounds as an effective component, in particular to provide a therapeutic and/or prophylactic agent for an autoimmune disease and the like. [Solving Means] Amino acid compounds that are represented by the following Formula (1) are provided

COORDINATION METAL COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE, MATERIAL FOR LUMINESCENT COATING FORMATION AND ORGANIC ELECTROLUMINESCENCE DEVICE

A coordination metal compound comprising cordinating at least one ligand having a spiro bond to at least a metal atom; a material for an organic electroluminescence (EL) device, and an organic EL device comprising at least one organic thin film layer sandwiched between a pair of electrodes consisting of an anode and a cathode, wherein at least one organic thin film layer thereof comprises the coordination metal compound or the material for an organic EL device, and a material for luminescence coating formation comprising an organic solvent solution containing the coordination metal compound or the material for the organic EL device is provided. Further, the organic EL device employing either the material for luminescence coating formation or the material for the organic EL device, which exhibits an enhanced efficiency of light emission and is superior in heat resistance, the coordination metal compound having excellent solubility for an organic solvent which realizes the aforementioned, the material for the organic EL device and the material for luminescence coating formation are provided.

Quinolonecarboxylic acid derivatives or salts thereof

PCT No. PCT/JP97/00317 Sec. 371 Date Aug. 10, 1998 Sec. 102(e) Date Aug. 10, 1998 PCT Filed Feb. 7, 1997 PCT Pub. No. WO97/29102 PCT Pub. Date Aug. 14, 1997The present invention relates to a quinolone-carboxylic acid derivative represented by the general